Skip to main content

Table 5 Haplotype analysis with different HCV outcomes

From: Genetic variants in antigen presentation-related genes influence susceptibility to hepatitis C virus and viral clearance: a case control study

a) Haplotype analysis of rs1063478, rs2284191, and rs11244 in sequence
Haplotype Uninfected N(%) Infected N(%) OR (95% CI) P
CGC 461 (47.8) 719 (49.6) 1.00
TGC 232 (24.1) 290 (20.0) 0.58 (0.47–0.73) <0.001
CGT 161 (16.7) 241 (16.6) 1.22 (0.94–1.58) 0.125
TAC 53 (5.5) 76 (5.2) 0.79 (0.53–1.17) 0.232
CAC 17 (1.8) 74 (5.1) 3.35 (1.87–5.99) <0.001
Others* 40 (4.1) 50 (3.5) 1.15 (0.71–1.87) 0.572
b) Haplotype analysis of rs17587, rs2071543, rs2284191, rs7383287, rs376892, and rs416622 in sequence
Haplotype Resolver N(%) Chronic N(%) OR (95% CI) P
GCGACG 101 (26.2) 213 (20.0) 1.00
GCGGCG 36 (9.3) 18 (1.7) 0.24 (0.13–0.45) <0.001
ACGACG 34 (8.8) 26 (2.4) 0.37 (0.21–0.65) 0.001
GAGACG 33 (8.5) 73 (6.9) 1.06 (0.66–1.71) 0.818
GCGGTA 24 (6.2) 38 (3.6) 2.37 (1.42–3.94) 0.001
GCGATA 13 (3.4) 89 (8.4) 3.31 (1.75–6.25) <0.001
GAGGCG 13 (3.4) 59 (5.5) 2.09 (1.09–4.02) 0.027
Others* 386 (34.2) 566 (51.5) 1.76 (1.28–2.41) <0.001
  1. Logistic regression analyses adjusted for age, gender, experience of blood/plasma donation, and numbers of blood/plasma donation.
  2. *Haplotypes with a frequency less than 5% in both groups were combined as others.